THE RECOVERY KERNEL

[illegible]

[illegible]:

* [illegible]
* [illegible]
* [illegible]
* [illegible]
* [illegible]
* [illegible]
* [illegible]

[illegible]

[illegible]:

* [illegible]

* [illegible]
* [illegible]

[illegible] [illegible] [illegible] [

[illegible] [illegible] [illegible] [

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] · GHB / GBL · [illegible] (4-MMC) · [illegible] · MDMA · [illegible] · [illegible]

⚠ [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] | [illegible] [illegible] [illegible]: **112** [illegible] [illegible] [illegible] [illegible] **9152987821** [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [

[illegible] [illegible] [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]—[illegible], [illegible], [illegible] [illegible] [illegible]—[illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] 0 [illegible] [illegible] [illegible]

[illegible] 0 - [illegible]: [illegible]

[illegible], [illegible]:

⚠ [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] **GHB + METH =** [illegible] [illegible] **GHB +** [illegible] = '[illegible]' [illegible] [illegible] [illegible] **GHB** [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible]	[illegible] [illegible]	**Response**
GHB [illegible] ([illegible] [illegible] [illegible] [illegible])[illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible], [illegible] [illegible]	[illegible] 112 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

		□□□□□□□□□ □□□□□□□□□□□□□□□ □□ □□□□□□□□□ □□□□□ □□□□ □□ □□□□□□□□ □□ □□□□ "□□□□□□ □□□□□" □ □□□□□.
□□□□ □□□□□□□□□, □□□□□□-□□□□□□□ □□□□ □□□□□□ □□ □□□□□□□	□□□□□□□□□ □□ □□□□□□□□□ □□□□ □□□□□□ □□□□□□□ □□ □□□□□□ □□□□□ □□□□ □□□□□□□□□ □□□□□ □□ - □□□□ □□□□□□□□□ □□ □□□□□□ □□ □□□□□ □□□□ □□, □□□□□ □□□□□□ □□ □□□□ □□□□□□□□□□□ □□ □□□□□ □□ □□□□ □□□□□ □□□□□ □□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□□	□□□□□ □□□□□□□□□ □□□□□□□, □□□□□□ (□□□ 72 □□□□□□ □□ □□□□□) □□ □□□□□□□ □□□□□□□□ □□□□□ □□ □□□□□□□ □□, □□□□□ □□□□□□□□□□ □□□□ □□ □□□□ RAINN □□□□□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□: 1-800-656-4673. □□□□□□□□□□ □□□□□□ □□□□□□□□□ □□□□□ □□ □□□□ □□□□□□□ □□ □□ □□□□□□ □□□□□□□ □□□□□□□

□□□□□□□ □□ □□□□ □□□□□□□ □□□□□□□□□□ (□□□□□□□) □□ □□□□ □□□□□□□□□□ □□□□□□□□□□□□□

□ □□□□□□□□□□ - 72 □□□□□ □□ □□ □□□□ □□ □□□□ □□□□□□ □□□□

□□ □□□□□□□ □□ □□□□□□□□□□ 42 □□□□, □□□□□□ □□ "□□□□□□□□□□ □□□□□□□" □□ □□□□ □□□□ □□□□□□□□□ □□□□□ □□□□ □□ - □□ □□□□□□□ □□□□□□□□ □□□□□□ □□ □□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□ □□ □□□□□□□ □□□□ 72 □□□□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□ □□□□□□□ □□□□ □□□□□ □□□□□□ □□ □□□□□ "□□□□□□□□□" □□□□□ □□ □□ □□□□□□□ □□ □□□□□□□ □□□□ □□□□ □□ □□□□ □□□□□□□□ □□, □□ □□□□□□□□□□□ □ □□□□□□ □□□□□□ □□□□□ □□□□□.

□□□□□□□□□□□	□□ □□□□□ □□□□□ □□□□	□□□□ □□□□□ □□ □□□□□□□
□□□□□□ (□□□□□□-□□□□□□□□□ □□□□□□□□□□□□□□□□)□	28 □□□□□□ □□ □□□□□□□□□□□□□□□□□ □□□□□□ □□ □□□□□□ □□ □□□□□□□□ □□□□□□ □□ □□□□ □□□□□□□ □□ □□□□□□□□ □□□□□□□□ □□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□□□□□□□□□ □□□□ □□ □□□□ □□□□□ □□□□□ □□ □□ 72 □□□□□□ □□ □□□□ □□□□□□ □□ □□□□□ □□□□	□□□□□ □□□□□ 72 □□□□□□ □□ □□□□□ □□□□□□□□□ □□ - □□□□□□ □□□□□□ □□ □□□□, □□□□□ □□ □□□□□□□ □□ □□□□□ □□ □□□□□□□□□□ □□□□□□, □□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□□□□ □□□□□□□□□ □□ □□□□ □□□□□□□ □□□□ □□ □□□□□□: "□□□□□ □□□□□□□□ □□□□□□□ □□□□□□ □□ □□□□ □□□□□□ □□ □□□□□□□□□ □□□□"
PrEP (□□□□□-□□□□□□□□□ □□□□□□□□□□□□□□□□).	□□□□□□ □□□□ (□□□□□□□□□□/□□□□□□□□□□) □□ □□□□□ □□□□ □□ □□□□ □□□□□ □□□□□ □□□□□□□□□□ (□□□□□□□□□□□□) □□ □□□□□□□ □□□□□□□□ □□ □□□□□□ □□ 99% □□ □□□□□ □□ □□□□□ □□, □□ □□□□□ □□□□□□□ □□□□ □□ □□□□□□ □□□□□ □□□□□ □□□□ □□ □□□□□□□ □□□□ □□□□ "□□□□□-□□□□□□□□□□□□□ □□□□□□□□□" □□□□ □□□□ □□□□	□□□□□□□□ □□□□□□ □□□□□□ □□ □□□□□, □□□□□□□, □□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□□□□ □□□□□□□ □□ □□□□□□□ □□ □□□□□□□ □□□□ □□□□□ □□□□ □□ □□□□ □□ □□□□□□□□ □□□□□ □□ □□□□ □□□□ □□ □□ "□□□□□□□□□□" □□□□ □□□□□□ □□□□, □□ □□□□□ □□□□□ □□ □□□□□ □□ □□□□□□□□ □□□□□ □□□□□ □□□□□.
STI □□□□□□□□ □□ □□□□□□□	□□□□□□□□□□, □□□□□□□□□□□□□, □□□□□□□, □□□□□□□, □□□□□□□, □□□□□□□□□□□ □ □□ □□ □□□□ □□□□□□-□□□□□□□ □□□□ □□□□□□ (chemsex) □□ □□□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□	□□ □□□□ □□□□□□ □□□□ □□ □□□□, □□□□□□ □□□□ □□ □□ □□□□□□□□□□□□ □□ □□□□ □□ "□□□□□□□□□□" □□□□ □□□□□□ □□□□, □□□□□□□□ □□□□□□□□ □□□□□□□□ □□ □□□□□□□□□ □□□□□ □□□□□ □□, □□ □□□□

	[illegible]	[illegible]
U=U ([illegible] = [illegible])	[illegible]	[illegible]

[illegible] - [illegible]

Naloxone (Narcan) GHB [illegible], [illegible] "[illegible]" [illegible] [illegible] [illegible]

□□□□□□□ 1 — □□□□□□□ □□□□□ □□ □□□□ □□□□□□□□□, □□□□ □□ □□□□□□□ □□ □□□□ □□□□□□□□□ □□□□□

□ □□□□□□□□□□ - □□□□□□□□□ □□□□ □□□□□ □□□□ □□□□ □□ □□ □□ □□□□□□□□□□□□ □□□□

□□□□□□□□□ □□□□□□□□□□□ - □□□□□□□□□ □□□□□□□□□□□□□□□, GHB/GBL □□ □□□□□□□□□□ (□□□□□ □□□□□□□□, MDMA, □□□□□□ □□ □□□□□ □□□□□□□ □□□□□□□-□□□□□□□□ □□□□□□□□□□ □□ □□□□ □□□□) - □□ □□□□ □□□□□□□□□□ □□□□ □□ □□□□□ □□□□□ □□□□ □□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□ □□ □□□□□ □□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□ □□□□□□□ □□, □□ □□ □□□□□□□ □□□□□□□□□ □□□□□ □□, □□□□ □□ □□ □□□□□ □□□□ □□ □□□□□□□□ □ □□□□□ □□□□ □□:

□□□□□□□□□ □□ □□□□□□□□□□□ □□□□□□□□

□□□□□□□□	□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□ □□□□□□□□□□ □□□□ □□□□ □□□□□ □□□□	□□ □□□□ □□□□ □□ □□□□□ □□□□□□ □□□□□□ □□?	□□□□□ □□ □□□□□□□□ □□?
□□□□□□□□□ □□□□□□□□□□□□□□□□	□□□□□□□□ □□□□□□□□□ □□ □□□□□□□□□□□□□□□□ □□ □□□□□□: □□□□□□□□ □□□□□□□□, □□□□□□, □□□□□□□□, □□□□-□□□□ □□□□□□□ □□ □□□□□□□ □□□□□□ □□□□ □□□□□ □□□□□□□□□, □□ □□□□□□□□□□□□ □□□□□□□ □□ □□ □□□□□ □□ □□ □□□□□□□ □□□□□□□□ □□ □□□□□□□ □□.	□□□□□□□ □□□□ □□□□□□□□, □□ □□□□□□ □□ □□□□□ □□□□□□ □□ □□ □□□□□ □□□□ □□□□□□□□ □□□□□□□□□ □□ □□□□□, □□□□□□ □□ □□□□□□□□ □□ □□ □□□□ □□ □□□□□ □□□□ □□□□□□□□□□□□ □□ □□□□□□□ □□□□□□ □□□□□ □□ □□□□□□□ □□□□ □□□□ □□□□□ □□ □□□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□□□□□□□□ □□□□ □□□□□□□□□□□	□□□□□□□□□ □□□□□□□□ □□ □□□□□□ (□□2 □□□□□□□□□□□□□□□)□ □□□□□ □□ □□□□□ □□□□□□□ □□□□□ □□□□□□ □□ □□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□ "□□□□□□□□□" □□□□ □□□□□ □□□□□ □□□□□□□ □□□□ - □□□□□□ □□□□□□□□□ □□□□□□□□ □□ □□□□□□□ □□ □□□□ 12-24 □□□□□□ □□□□□ □□□□.
GHB/GB □□ □□□□□□ □□□□□ □□ □□□□□□: * □□ □□□□ □□ □□ □□ □□□□□ □□□□ * □□ □□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□ □□ □□□□□ □□, □□□□□ □□ □□□□□ □□□□□ □□□□ □□□□□□, □□□□□ □□ □□□□□□ * □□ □□□□□□□ □□ □□□□□ □□ □□□□□ □□□□ * □□□□ □□	□□□□□□□-□□ □□□□□□□□□: □□□□□□□□□□□□□□□, □□□□□□□, □□□□□□□□ □□□□□, □□□□□□□ □□□□□□□□ □□□□ □□ □□□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□□ □□ □□ □□□□□ □□ □□□□□ - □□□□□□□ □□□□□□□□ □□□□□□□ □□ □□ □□□□□ □□□□□ □□□□ □□ □□□□□ □□□□□ □□□□□ □□ □□ □□□□□□ □□□□ □□□□□ □□ □□ □□ □□□□□ □□.	□□□□□□□□ □□ □□□□□□□ □□□□□□□□ □□ □□□□ □□□□□□ □□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□□ □□ □□ □□□□□□ □□□□□□□□□□□□□ □□□□ □□□□□ □□ □□□□ □□□□□□□□□□□□, □□□□□□□ □□ □□□□□□□□□□□ □□□□□□□□□□ □□ □□□□□□□ "□□□□□□□□□ □□□□□□□" □□ □□□□□□□□□	□□□□□ □□□□□□□ □□□□□□□, □□□□□□□ □□□□□□□ □□□□□□ □□ □□□□ □□□□□ □□□□ □□□□□□ □□ □□□□ □□□□□□ □□□□ □□□□□ □□ □□□□□□□□□□□ □□ □□□□□ □□□□□ □□□□ □□□□ □□□□□□□□□ □□□□ GBL □□ □□□□□□□□□□ □□ □□□□□□□ □□ □□□□□ □□□□ □□ □□□□□□ □□□□□□□□□ □□□□ □□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□ □□□□□ □□□□

GHB/GB □□ □□□□□□ □□□□□ □□□□ □□ □□□□□ □□□□ □□□□□□□ □□□□□ □□, □□ □□□□□□□ □□□□□□□□□ □□□□□□□ □□□□□ □□□□ □□ □□ □□□□□ □□□□ □□□□□□ □□□□□ □□□□□□□□ □□□□□□□ □□ □□□□ □□□□□□□ □□ □□□□ □□, □□ □□□□□□ □□□□ □□ □□□□ □□□□□□□ □□□□□□ □□ findahelpline.com □□ □□ □□□□□ □□□□ □□ □□□□□ □□□□□□□□□□ □□ □□□□□□□ □□ □□□□□ □□□□□			
□□□□□□□□□□ / □□□□□□□□	□□□□□□□ □□□□□□□□ □□□□□□□□□ (□□□□□□□□□□, □□□□□□□□□□, □□□□□□□□□□□□□□□□□), □□ □□□□□□ □□ □□□□□ □□, □□□□□□ □□□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□□□□□□□□□□□□□ □□□□□□□ □□ □□ □□□□□ □□□□□ □□□□□ □□: □□ □□ □□□□□□□□-□□□□□□□□□□ □□□□□□□□□□□ □□□□ □□ □□□□□ □□□□□□ □□□□ □□□□ □□□□□ □□.	□□□□ □□□□□□□□□□ □□ □□□□□□□□ □□□□□□□□□□ □□□□□□□ □□ □□□□□□□□ □□□□□□□□ □□ □□□□□ □□□□ □□ □□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□ □□ □□□□□□ □□□□□□ □□□□ □□□□□□□□ □□□□□ □□ □□□□ □□□□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□ □□□□ □□□□□□□ □□□□□□□ □□ □□□□□□, □□□□□ □□□□ □□□□□□ □□ □□□□ □□□□□□□□ □□□□□ □□□□ □□□□□ □□ □□□□ □□□□□□ □□□□□ □□□□	□□□□□ □□□□□□□ □□□□□□ (□□□□□ □□□□□□ □□□□ □□□□□ □□□□□□□)□ □□□□□□□□□□ □□□□□□□□□□ □□ □□□□□□□□□ □□□□□□□□ □□ □□□□□ □□□□□□□□□□ □□□□□□□□ □□□□ □□□□□□□□□ □□□□□ □□ □□□□□□□□ □□ □□□□□□□ □□ □□□ □□ □□□□□ □□□□-□□□ □□□□ □□□□□ □□ □□□□ □□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□, □□□□□□□ □□□□□□ □□ □□□□□□ □□□□□
MDMA (□□□□□□ □□□□□□□□□ □□□□□ □□□□□ □□)	□□□□□□□□□□ □□ □□□□□ □□□□□□: □□□□□□□□□□□ □□ □□□□□□, □□□□□□□□□□ □□□□□□□□□, □□□□□□□□□□□□□□□□ □□□□□□□, □□□□□□□ □□□□□□□□ □□□□ □□□□□□□, □□□□□□ □□□□□□ □□□□ "□□□□□□□□□" □□□□ □□□□□□ □□□□□ □□□□□ □□ □□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□ □□□□□ □□□□□	□□□□ □□□□□□□□□□ □□□□□□□ □□ □□□□□□□□□□ □□ □□□□□□□ □□□□□□□ □□□□ □□□□□ □□ □□□□□□ □□ □□□□□□□ □□□□ □□□□□ "□□□□□□ □□ □□□□" □□ □□□□□□□□ □□□□□□ □□□□□ □□ □□□□ □□□□□ □□□□□ □□, □□□□□□ □□□□-□□□□□□□□□□ □□□□□□□□ □□ □□□□□□□ □□□□□	□□□□-□□□□ □□□□□□□□□ □□□□□ □□ □□□□□□□□□□ □□ □□□□□□□□□□□□□□□□□□ □□ □□□□□ □□□□ MDMA □□ □□□□ □□□□□ □□□□□ '□□□□□□□□ □□ □□□□□□' □□□□□□□□□□ □□ □□□□ □□ □□□□□ □□□□□ □□ - □□□□□□ □□□□□□□□□, □□□□□□ □□ □□□□□□□□ □□□□□□ □□□□□□ □□□□□ □□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□ □□ □□□□ □□□□□ □□ □□□□□□□□□□ □□ □□ □□□□□□ □□□□□ □□□□□□ □□□□ □□□□□□□□□ □□□□□ □□ □□□□□□ □□□□ □□□□□□□□ □□□□□□□□□□

			[illegible]

[illegible]?

[illegible]

Understanding chemsex recovery requires understanding what the experience itself was providing — not the individual drugs, but the totality of the state they created together. The compendium names the individual substances as 'the Chemsex Daemon' that 'disables the user's native threat detection algorithms.' But this framing, while accurate for harm reduction purposes, describes the mechanism while underselling the power of what was being sought.

[illegible] "[illegible]" [illegible]:

- [illegible]
- [illegible]
- [illegible]
- [illegible]
- [illegible]

[illegible] [illegible] [illegible] [

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] * [illegible]-[illegible] [illegible] [illegible] [illegible]-[illegible] [illegible] [illegible] * [illegible] [illegible] [illegible] [illegible] [illegible] GHB/GB [illegible] [illegible] [illegible] * [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] GHB/GB [illegible] [illegible] [illegible] * [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] GHB/GB [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

	[illegible] [illegible]		[illegible] [illegible] "[illegible]" [illegible]
[illegible] / [illegible]	[illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible]	[illegible] 1-5 [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].	[illegible], [illegible], [illegible], [illegible] [illegible] [illegible], [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] 2 — [illegible]

[illegible], [illegible]: COMT Val/Val ([illegible] - [illegible]) [illegible] MTHFR [illegible] ([illegible])। [illegible], [illegible], [illegible]-[illegible]:

[illegible]	[illegible]	[illegible]	[illegible]
COMT	Val/Val (rs4680) — [illegible]	[illegible] COMT [illegible], [illegible] [illegible], [illegible] "[illegible]" [illegible]।	[illegible] - [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible]।
MTHFR	C677T (rs1801133) [illegible] A1298C (rs1801131).	[illegible] - [illegible], [illegible], [illegible]।	5-MTHF [illegible] MTHFR [illegible] "[illegible]" [illegible] - [illegible] "[illegible]" [illegible].
GABRA2	rs279858 / rs279845 [illegible]	GHB [illegible]-[illegible]	GABRA2 [illegible], GHB [illegible]-[illegible]

	□□□□□□□□□□.	□□□□□□ □□□□□ GABRA2 □□□□□ □□□□ □□□□□ □□ □□□□□□□□□□ GABAergic □□□□□□□□□□□□ □□□□ □□□□□ □□ - GHB □□ □□□□□□□□□□□□ □□ □□□□□□□□ □□□□□ □□□□□□□ □□□□□ □□, □□ □□ □□□□ □□□□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□□□□□ □□ □□□□□□ □□□□□.	□□□□□□□ □□, □□□□□□□□ □□□□□□□ □□□□□ □□□□□□ □□□□□□-□□□□□□□□□□□□□ □□□□□□□□ (PAWS) □□□□□ □□ □□□□□ □□□□□ □□ □□ GABA □□ □□□□□□□□ □□□□□ □□□□ □□□□□ □□□□ □□□□ □□□□□ □□□□ □□ □□□□□ □□□□ □□ □□□□□□□□ GHB □□□□□□ □□ □□□□□□ □□□□□ □□□□□□ □□ □□□□□□ □□ □□□□□□□□□□ □□□□□ □□□□ □□ □□□□□□□□□□□□ □□, □□ □□□□□□□□□ □□□□ □□ □□□□ □□□□□□□ □□□□□□□□ □□.
DRD2 / ANKK1	Taq1A A1 □□□□□ (rs1800497) — □□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□	□□□□ □□□□ DRD2 □□□□□□□□□ □□□□□□ □□ □□□□□ □□ □□ □□□□□□□□□ □□ □□□□□ □□□□□□□ □□ □□□□□ □□, □□□□□□ □□□□□ □□ □□□□ □□□□□ □□ □□□□□□ □□□□□□ □□□□□ □□□□□ □□ □□ □□ □□□□ □□ □□□□ □□ □□□□□ □□□□□□□□□ □□□□ □□ □□□□ □□ □□□□□□ □□ □□□□□□□□□ □□□□□ □□□□□□□□□ □□ □□□□□ □□□□□□□ □□□□□ □□, □□ □□ □□□□□□ □□ □□□□ □□ □□□□ □□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□ □□ □□□□□□□□ □□□□□□□□ □□□□□ □□.	DRD2 A1 □□□□□ □□□□□ □□□□□□□□ □□ □□□□□□□□ □□□□□ □□ □□ □□□□□ □□ □□ □□□□□ □□ □□□□ □□□□□□□□□ □□□□□□□□ □□ □□□□□□□□□ □□□□□ □□, □□□□□□□ □□□□□ □□ □□□□□□□□□ □□□□□□□□ □□□□-□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□ □□□□ □□□□□□□□□□ □□□□□□ □□□□□□□ □□□□□□□ □□□□ □□□□-□□□□□ □□□□□ □□□□□ □□□□□□.
DAT1 / SLC6A3	10-□□□ □□□□□□□ □□ VNTR □□□□□ (rs28363170).	□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□ = □□□ □□□□□□□□□ □□□□□ □□□□□□□ = □□ □□□□□□□□ □□□□□□□□□ □□□□□□□□□ = □□□ □□ □□□□□□ □□□□□□□ □□ □□□□□□ □□□□□□ □□□□□□□□□□□□□□ □□ □□□□□□□□ □□ □□ □□□□□□□ □□ □□□□□□ □□ - □□□□□□□□ □□ □□□□ □□□□ □□ □□ □□□□-□□□□ □□ □□□□□□□□□ □□□□□□-□□□□□□ □□□□□□ □□□□
ADHD □□□□□□□□□□, □□□□□□ □□□□□□ □□ □□□□□□ □□ □□□□□□□□□□ □□□□ □□□□□□□□□□□ □□□□ □□ □□□□□□□□□□□ □□□□ □□ □□□□□ □□ □□ □□□□ □□ □□□□□□ □□□□□□□□□ ADHD □□ □□□□□□□□ □□ □□ □□□□□ □□ □□□□ □□□□□ □□ □□□□ □□□□ □□□□-□□□□□□□□ ADHD □□□□□□ □□□□□□□□□□□□ □□□□□□□ □□ □□□□□□□□ □□□□□ □□ □□ □□□□ □□ □□□□ □□ □□□□□□ □□ □□ □□□□□ □□ □□ □□□□ □□□□□ □□□□
SLC6A4 / 5-HTTLPR	□□□□□□/□□□□□□ □□□□□ — □□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□	□□□□□ □□□□□□ □□□□□□□□□□□□□□, □□□□□ □□ □□□□□□□□ □□□□ □□□□□□□□ □□ □□□□□ □□□□□□, □□ □□□□□□□□□□□	□□□□□□□□□□ □□□□□□□□□□□□□□□, □□□□□□□6□4 □□ □□□□□/□□□□□ □□□□□□□ □□□□, □□□□□□□□□ □□□□□□□ □□ □□□□ □□ □□□□□□□□□ □□□□□□□ □□□□ □□□□□□ □□ □□□□□ □□ □□□□□□□□□ □□ □□□□□ □□□□□□

	[illegible]	[illegible] [illegible] [illegible]

□□□□ 3 - □□□□□□□ □□□□□□□□ - □□□-□□□□□ □□□□ □□ □□□□□□□□□ □□ □□□ □□□□□□□□.

□ □□□□□□□□□ — □□□ □□□□□ □□□□, □□ □□□□□□□, □□ □□□□□□□ □□□□□

□□□□□□□□ □□□□□ □□ □□ □□ □□□ □□ □□□□ □□ □□□□ □□□□ □□ □□□□□ □□□ □□□□□ □□□□□□□□ □□ □□□, □□□ □□□-□□□ □□□□□ □□□□□□□ □□□□□, □□□□□ □□ □□□□□□□□ □□ □□□□ □□□□□□□, □□□□□□□□ □□□□□□□□□□ □□ □□□□ □□□□□ □□□□□ □□ □□□□□□□ □□-□□□□ □□ □□□□□ □□□□ □□□□□ - □□ □□ □□□ □□□□ □□□, □□ □□□□ □□□□□ □□□□ □□□

□□□□□□□ □□ □□□□□□□□: □□□□ □□□□ GHB □□ □□□□ □□□□ (□□ □□ □□□□□□□□ □□□□□□□ □□), □□□ □□□ □□□ □□ □□□ □□□□□□□□ □□ □□□□ □□□□□ □□□□□□□ □□□□□□□ □□□□, □□ □□□ □□□ □□□□-□□□□ □□□□□□□□□□ □□ □□□□□□□□ □□□□□□□□□□□□□□ □□□□□ □□ □□□□□□□ □□□□□

□□□□□ 1: GHB/GBL - □□□□□□□□ □□□□□□□□□□□

□□□ □□ □□□ □□□ □□□ □□ □□□□ □□□ GHB/GBL □□ □□□□ □□ □□□ □□□, □□ □□ □□□□ □□□□□□ □□□□□□□□ □□□□□□□□□□ □□□ GHB □□ □□□□□□ □□□□□□□ □□ □□□□□ □□□□□□□□ □□□□ □□ □□□□□□ □ □□□□□ □□ □□□□□□□□ □□□ □□□ □□ GHB □□□□ □□ □□□□□□□ □□□□ GHB □□□□□□□□□ □□□□ □□□□□ □□□□□ □□□□□:

- □□□□□□□□□ □□ □□□□-□□□□ □□□ □□□□, □□□□□□ □□ □□□□□□ □□□ – □□ □□□□□□-□□ □□□□□ □□ □□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□
- □□□ □□□□□□□□□ □□□□□□ □□□□ □□, □□ □□□□□□□□□□ □□□□□□ □□□ □□□□ □□□□□ □□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ □□ □□□□□ □□□□ □□ □□□□ □□□
- GABRA2 □□□ □□□ □□□□□ □□□□□, □□□ □□ □□□□□ □□□□-□□□□ □□ □□□□ □□ □□□ □□ □□□□□□□□ □□□□ □□□□ □□□ □□□□□ □□□ □□□□ □□□□□ □□□□ □□□□□ □□□ □□□□ □□□, □□□□□□ □□□ □□ □□□□□ □□□□-□□□□ □□ □□□□ □□ □□□□□□□□ □□□□ □□.
- □□□□□□□□□ □□□□□ □□□ 1 □□ □□□□ □□□□: □□□□□□□□□□ □□□□□□□□□□ (400–600 □□□□□□□□□, □□□□□□□ □□□□□), P5P (25–50 □□□□□□□□□), 5-MTHF (400 □□□□□□), □□-□□□□□□□ (200–400 □□□□□□□□□, □□□□□□□□□□□□□)□
- □□□□□□ (□□□□□□□□□□□) □□ □□□□□ □□□□□ □□□□□□□ □□ □□□ □□□□□□□ □□ □□□□□ □□□□ □□ □□□□ □□□ □□ □□□-□□□□□ □□□ □□ □□ □□□□ GABA-B □□□□□□ □□ □□□□□□□ □□.
- □□□ Talon, □□□ □□□ □□□ □□□□ □□ □□□ □□□□ □□ □□□ □□□□ □□ □□□□□□□□□ □□ □□□□□ □□□□ □□ □□□□□□ □□ □□□□□□□ □□□□ □□□ □□□ □□□□ □□□

□□□□□ 2: □□□□□□□□ □□□□□□□□□□□□□ - □□□□□□□□ □□□□□□□□□□□□.

□□□ □□ □□□□□ □□ □□□ □□□□ □□□□ □□, □□□ □□ □□□□□□ □□ □□□ □□ □□□□□□□□ □□□□□□□ □□□□ □□□□ □□□ □□□ □□ □□□□ □□□□ □□□□□□ □□ □□□□ □□□ □□□□□□ □□□□□□□□ □□□□□□□ □□□□ □□□□ □□ - □□□□□ □□ □□□□□ □□ □□□□ □□□□ "□□□□□□□□" (chemsex) □□□□ □□ □□□ □□□ □□□□ □□□ "□□□□□" □□□□□ □□□□□□□ □□□ □□□□ □□□□□ □□□□□□□□□□□□ □□□□□□□□□ □□□ □□ □□ □□□ □□□□ □□□ □□□□□ □□□□.

- [illegible] [illegible] [illegible] [illegible] [illegible]: [illegible] 01 ([illegible]), [illegible], [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] (500-1000 [illegible], [illegible], [illegible] [illegible]): [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] 3-5 [illegible] [illegible].
- NAC (600mg [illegible] [illegible], [illegible] [illegible]): [illegible] [illegible]; [illegible] [illegible].
- [illegible] + [illegible] + [illegible]-[illegible] ([illegible] [illegible]): [illegible]2 [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] - BDNF [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- Semax ([illegible]): BDNF [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].
- BPC-157: [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] 3: [illegible] [illegible] - [illegible] [illegible].

[illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] ([illegible] [illegible] [illegible]), [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

0-72 [illegible]	[illegible] [illegible] [illegible]

	[illegible] [illegible], [illegible] [illegible] [illegible]

□□□□□□□ 4 - □□□□□□ □□□□□□□□□□□□□ - □□□□□□□ □□□□□□

□□ □□□□□□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□□, GHB, □□□□ □□ □□□□□□□/□□□□□□□□□□□ □□□□□□□ □□ □□□□-□□□□ □□□□□□□□ □□□□□ □□ □□ □□□□□□ □□□□□□□□□□ □□ □□□□□□ □□□□□□□□□□ □□□□□□□□ □□□□□□□ □□□□ □□□□□ □□□□□□□: □□ □□□□ GABA-B □□□□□□□ (GHB □□□□□□), □□□□□□□□□□ □□□□□□□□□□ □□ D2 □□□□□□ (□□□□ □□□□□□) □□ □□□□□□□□□□□ □□□□□ (□□□□□□□□□□□/MDMA □□□□□□) □□ □□□□ □□ □□□□□□ - □□□□ □□ □□ □□□□□□□□□□□ □□□□□ □□ □□□□□□□□ □□□□□ □□ □□□□□□ □□ □□□□ □□□□□□□□□□□□□ □□□□

4.1 — □ □□□□□□□□□□ □□□□□□□□□ — □□□□ □□□□□ □□ □□□□ □□□□□□□□□□

□□□□□	□□□□□□□	□□□□□	□□□□□ □□□□□ □□□□□, □□□□ □□ □□□□□ □□ □□□□□ □□□□□ □□ □□□□□□
5-MTHF (L-□□□□□□□□□□□□□)	400–1000 mcg □□□□□□□□□□	□□□□□ □□ □□□□□□□□	□□ □□□□□□ □□□□□□ □□□□ □□ MTHFR □□□□□□□□ □□ □□□□□□□□□ □□□□□□□ □□ □□□□□□ □□□□□ □□ □□□□□□□ □□ □□□□□□□ □□□□□□□□ □□ □□□□□□ □□ □□□□□□□ □□□□□ □□□□□ □□□□ 5-MTHF □□□□□ □□□□ □□ □□ □□□□□□□ □□ □□□□□□□ □□□□□ □□ - □□ □□□□□□□ □□□□□ □□ □□□□□□□□□ □□□□□□□ □□ □□□□□□□ □□ □□□□□□□ □□□□□ □□ - □□ □□□□ □□, □□ □□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□ □□ □□□□□□□ □□□□□□□ □□□□□ □□, □□ □□□□ □□□□ □□□□□□□ □□□□□□□□ □□ □□□□ □□□□□□□ □□□□ "□□□□□□□□□□" □□ □□□□□□ □□□□□□ □□ □□□□, □□ □□□□□ □□□□□□□□□□□ □□□□□□□□□□ □□, □□□□□□□□ □□ □□□□□□□ □□□□□□□□ □□ □□□□□□□□ □□□□□□ □□□□□ □□ □□□□□□□□□ □□□□□□□□□ □□□□□□□ □□□□□□ □□ □□□□□□□□ □□□□□ □□□□
□□□□□□□□□□□□□□□□□□ (□□12)	1000–2000 mcg □□□□□□□□□□.	□□□□ □□□□□□□□	□□ 5-MTHF □□ □□□□ □□□□□□□ □□□□□□□ □□□□ "□□□□□□□□□" (□□□□□□□□□, □□□□□□□□□□ □□ GABA □□ □□ □□□□ □□□□□□) □□□□□ □□ □□ □□□□□□□□□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□□□ □□, □□□□□□ B12-□□□□□□□ □□□□□□□□□ □□□□□□□□ □□ □□□□□ □□□□□□ □□□□ □□□□□□ □□□□□□□ □□ □□□□ □□□□□□□□□□□ (□□□□ □□ □□□□□ □□□□□ □□□□□) □□□□□ □□ □□□□□□□ □□ □□□□□□□ □□ □□□□□ □□□□□ □□□□ □□□□ □□□□□ □□, □□ □□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□□□□□ □□□□□□□ □□□□□□ □□ □□□□ □□□□□□□□□□□□ □□.□
P5P (□□□□□□□ □□□□□□□□ □□6)	25–50mg	□□□□ □□□□□□□□	□□□□□□□□□□ □□ GABA □□□□□□□□□ (GHB □□ □□□□□□), □□□□□□□□□

			□□□□□□□□□ (□□□ □□ □□□□□), □□ □□□□□□□□□ □□□□□□□□ (□□□□□□□□□ □□ □□□□□) □□ □□ □□□ □□□□□□□□ □□□□ □□□□ P5P-□□□□□□ □□□□□□□□ □□ □□□□□□□ □□□□ □□□□□□□□ □□□ □□□□□ (chemsex) □□ □□□ □□□□ □□ □□□□□□□□□ □□□ □□□□ □□□ □□ □□□ □□□ □□□□□□ □□ □□□□□□□ □□□ □□□□□□□□.
□□□□□□□□□□ □□□□□□□□□□	400-600 □□□□□□□□□ □□□□□□□□□	□□□□ □□ □□□□	□□□□□□ □□□□□□□□□ □□□□ □□□□□□□ □□□□□□□□ □□ □□□ □□□ □□ □□ □□□□□ □□ □□ □□□ □□□□□□ □□□□ □□: GABA-B □□□□□□ □□□□□□ (GHB □□□□□) □□ NMDA □□□□□□/□□□□□ □□ □□□□ (□□□ □□□□□□□ □□□□□)□ □□ □□□□ □□□□□□ □□□□□□□ □□ □□ □□□□□□ □□□□ □□ - □□ □□□□□□□□□ □□ □□□□□□□ □□□□□□□□ □□ □□□ □□□□□ □□□□ □□□ □□□□□□□ □□ □□□□□.

4.2 — □□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□

□□□□	□□□□□□	□□□□	□□□□□□□□ □□□□□□	□□□□□□□□□□
L-□□□□□□□□	500–2000mg	□□□□, □□□□□□□ □□ □□□□	□□□/ □□□□□□□□	□□□ 3-5 □□ □□□□ □□□□ □□ □□ □□□□□□ □□□ □□ □□ □□□ □□□□ □□□□□□□ □□ □□□□□□ - □□ □□□ □□ □□□□□ □□ □□□□ □□□□ □□□□□ □□□ □□ □□□ □□□□ □□□ □□□□□□ □□ □□□ □□□□ □□□□ □□□□□□ □□□□□ □□ □□□□
NAC	600-1200 □□□□□□□□□, □□□ □□□ □□ □□□□	□□□□ □□ □□□, □□□□ □□ □□□□	□□□ □□□□□□	□□□□□□□□□ □□□□□□□□□□□□□□, □□ □□□ □□□ □□□□□□ □□ □□□ □□□□□□□□ □□□ □□□ 1 □□ □□□□ □□□□□ □□□ □□□□□□ □□ □□ □□ □□□ □□□□□□□□ □□ □□□□ □□ □□□□□ □□□□□ □□□ □□ □□□□ □□ □□□□□.
□□□□□□□□ + □□□□□ +	250mg UMP	□□□ □□□□□□□	□□□/	D1/D2 □□□□□□□□ □□

[illegible]-[illegible] ([illegible])	+ 1g DHA + 250mg CDP-choline.		[illegible]	[illegible] - [illegible], [illegible], [illegible]
5-HTP	50–100mg	[illegible], [illegible] 30 [illegible]	[illegible] / [illegible] / [illegible]	[illegible] - [illegible] ([illegible] + [illegible] + [illegible]) [illegible]
L-Theanine	200–400mg	[illegible], [illegible] 2-3 [illegible]	GHB/ [illegible]	GABAergic [illegible] NMDA-[illegible], [illegible]-[illegible] GHB [illegible]-[illegible] GABA [illegible]
[illegible]	1-2 [illegible]	[illegible]	GHB / GABA	[illegible]; [illegible]; [illegible] - [illegible], [illegible]

				□□ □□□□□ □□□□□
Inositol.	4–12g (□□□□□ □□□□□□□□ □□□□)	□□□□□□□ □□□□□	□□□□□□□□□ / □□□□□□□□□	□□□□□□□□ □□□□□□□ □□□□□□□□□; □□□□ □□□ □□□; □□□□ □□ □□□□□□□□ □□□□□□ □□ □□□□□□ □□□ □□ □□ □□□□□ □□□ □□□□□□□□ □□ □□□□ □□□ □□ □□ □□□□ □□□ □□□□□□□□ □□ □□□□□ □□□□ □□□□□ □□, □□ □□□□□ □□□□□□□ □□ □□□□□ □□□□ □□□
□□□□□-3 □□□□ + □□□□□	2-4 □□□□□ □□□□ □□□	□□□□ □□ □□□, □□□□□	□□□ □□□□□	□□□□-□□□□□□□□

	[illegible]		
BPC-157	[illegible]; [illegible]-[illegible]; [illegible]-[illegible]; [illegible]-[illegible]; [illegible].	[illegible] - [illegible]-[illegible]	[illegible] - [illegible] ([illegible]), [illegible] ([illegible]), GABA-B (GHB) [illegible] ([illegible]) [illegible] 1 [illegible].
Selank	[illegible] GABA [illegible]; [illegible]; [illegible] GHB [illegible].	GHB [illegible]	[illegible] - [illegible] GHB [illegible] GABA [illegible]/[illegible] [illegible]-[illegible], [illegible].
Semax	BDNF [illegible] NGF [illegible]; [illegible]; [illegible]; [illegible].	[illegible] - [illegible]	[illegible], [illegible] "[illegible]" [illegible], [illegible] BDNF ([illegible]-[illegible] [illegible]) [illegible], [illegible] 1 [illegible]
[illegible] Talon	[illegible]; [illegible]; [illegible]	[illegible] - [illegible]	[illegible] GHB [illegible], [illegible], [illegible] GHB [illegible]-[illegible]

			□□□□ 4-6 □□□□□□□□

[illegible] 5 - [illegible] [illegible]

[illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

- [illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] (ECG) [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [

	[illegible] [illegible] [illegible]	
[illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible]

□□□□□□□□□□ □□□□□ □□ □□□ □□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□ □□□ □□ □□□ □□□ □□ □□ □□□□ □□□□□□□□ □□□□□□□□□ □□ □□□□ □□ □□-□□□□□ □□ □□□□ □□ □□□□ □□□□ □□ □□□□□□□□ □□□□□□□□ □□□□□□ □□□□□ □□, □□□ □□□□□□□□□ □□□□□□ □□□□□

- □□□□□ □□□□□ □□ (□□ □□□ □□□□□ □□□□ □□□ □□□□ □□): □□ □□□□□□□ □□□□ □□ □□ □□□□□ □□□□ □□□□□□ □□□□□□□ □□ □□□□□□ □□□□□ □□ □□ "□□□□□-□□□□□□□, □□□□□-□□ □□□□□□" □□□□ □□□□ □□□□□ □□ □□□□ □□□□ □□□□ □□, □□□□□□ □□□□□□ □□ □□□□□□□□ □□□□□ □□ - □□□ □□ □□□□ □□□ □□□□□ □□ □□□□□□ □□□ □□□□ □□, □□ □□□ □□□ □□□, □□ □□□□□□ □□□□□□□□ □□ □□□ □□□ □□ □□□□ □□□□ □□ □□□□ □□□ □□ □□□□□□□□□□ □□ □□□□□□ □□□□ □□□□□□□ □□□□ □□□□□□□□ □□□□□ □□□□ □□□□ □□□□□□□□□ □□□□□□ □□ □□□ □□ □□□.

- □□□ □□□□: □□ □□□□□ □□ □□□ □□ □□□□□□ □□□□□ □□ □□□ □□□ □□□, □□□□□ □□ □□□□□ □□ □□□ □□□□□□□□□ □□□ □□□□□□□ □□ □□□□□□□ □□ □□□ □□□□□□□□ □□□□□□□□□□ □□ □□□□□ □□□□ □□ □□ □□□ □□□ □ □□□□ □□ □□□□□ □□ □□□□□□□ □□□□ □□, sobriety □□□□ □□□ □□ □□□ □□ □□□□ □□ □□□□ □□□ □□□ □□ □□ □□□ □□ □□□□□□ □□□□ □□ □□ □□□ □□□□□ □□□□□ □□□ □□□ □□ □□ □□□ □□ □□□□□□ □□ □□ □□□□ □□□□□□ □□□□□ □□ □□□□□ □□□□□ □□ □□ □□□□ □□□ □□□□ □□ □□□ □□□□□□□□□□ □□□□□ □□□□ □□ □□□□□□□□□ □□□ LGBTQ+ □□□□□□□ □□□□□□□ □□ □□□□□ □□ □□□ □□□□□□□ □□□□□□□ □□□

- □□□□□□□ □□□□□□□ □□ □□□ □□□□□: □□□ □□□□□□□ □□□□□□□□ □□□ - □□□□ □□□ □□ □□□ □□□□□ □□□ □□ □□ □□□□□□□ □□□□□□□□ □□ - □□ □□□ □□□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□, □□□□□ □□ □□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□ □□ □□□□□ □□□□□ □□, □□□ □□ "□□□□□□□□□□□□□□□ = □□□□□□□□□□□□□□□□□□□" (U=U) □□ □□□□□□□□□□□ □□□□□□□□□□□ □□ □□ □□□□□ □□□□□□□□□□□ □□□ □□□ □□□ □□□□□□□ □□ □□□□□ □□□ □□□ □□□□ □□ □□□ □□, □□ □□ □□□□□□□ □□□□□□□□ □□□□ □□ □□□□□ □□ □□□ □□□□□□□□ □□ □□□□□□□□□ □□ □□□□□ □□□ □□ □□□ □□□□ □□ - □□ □□□□□ □□ □□□, □□ □□ □□ □□ □□□ □□□□ □□ □□ □□□□□□□ □□□□□□□ □□□□ □□ □□□□□ □□□ □□□□ □□□□□ □□□ □□□□□□□ □□ □□□□□□□ □□ □□□ □□□

- □□□□□□□□□, □□□-□□□□□□□□□ □□ □□□ □□□□□□□: □□□□□□, "□□□□□□□□□" □□□ □□□□□□□□ □□□□□□□□-□□□ □□□□□□□□□ (□□□□□, □□□□□□, □□□□ □□□□□□□□) □□□ □□□□ □□□ □□□□□□□ □□ □□□ □□□□□□□□□ □□ □□□□ □□□□□□ □□□ □□□□□□□□ □□ □□□□□□□ □□ □□□□□□□□□ □□□□ □□□□ □□□ □□□□ □□□ □□□□□□□□ □□ □□□ □□□□□□□□□□ □□□□ □□□□ □□□□ □□ □□□ □□□□□□□ □□ □□□□□□□□ □□ □□□ □□ □□□□□□□ □□□□□ □□□□□□□ □□□ "□□□□" (□□□□□□□) LGBTQ+ □□□□□□□, "□□□□" □□□ □□□□□□□ □□ □□□□□□□ □□□ □□ LGBTQ+-□□□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□ □□ □□□□□□□ □□□□□ □□ □□□□□ □□□

□□□□□□□ 6 - □□□□□□□ □□□□ □□□□□□□ □□ □□□□□□□□□□□ □□□□□□□□□

□ □□□□□□□□□□□ — □□□□□□□□□□ 42 □□□□□ — □□□□□□-□□□□□□□ □□□□□□□□□□□□ □□ □□□□ □□□□ □□□□□□□□ □□ □□□□ □□□□□□□□□□ □□□□□□□

□□ □□□□□□□ □□ □□□□□□□□□□□□ 42 □□□□□□□ □□□□□□□ □□ □□□□□□□□ □□ □□□□ □□ □□□□□□□□ □□□□□□ □□□□□□□ □□□□□ □□□□ □□ □□□□□□□ □□□□ □□□□□□ □□□□ □□ "□□□□□□□□□" □□ □□□□□□ □□□□□□ □□ □□□□□ □□□□□ □□□□

6.1 — □□□□ □□ □□□□□□□ □□□□□□□□□ □□□□□

- PrEP (Pre-Exposure Prophylaxis): □□□□ □□ PrEP □□□□□ □□ □□□□ □□□□ □□ □□□□□ '□□□□□□□□□' □□□□ □□□□ □□□□□ □□, □□ □□□□□ □□ □□□□ □□□□□□□□ □□ □□□□□ PrEP □□□□□ □□□□□□ □□ □□□□□ □□ '□□□□□-□□□□□□□□□□□□ □□□□□□□□' □□□□ □□□□ □□□□ Truvada □□ Descovy (□□□□□□ □□□□□□ □□□□) □□ Apretude (□□□□□□□□□, □□ 2 □□□□□□ □□□□) □□□□ HIV □□ 99% □□ □□□□□ □□□□□□□□□ □□□□□□□ □□□□□ □□□□, □□ □□□□□ □□□□□□□ □□□□ □□ □□□□□□ □□□□□ □□□□□ □□□□ □□ □□□□□ □□□□□□□□ □□□□□□□□□, □□□□ □□□□□□□□□□□ □□□□□□□□ □□ □□□□□□□ □□□□□ □□□□□□□ □□ □□□□□□□ □□ □□□□□□□ □□□□□
- PEP (□□□□□□-□□□□□□□□□ □□□□□□□□□□□□□□□□): □□□□ □□□□□ "□□□□□□□□□" □□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□ □□, □□ PEP □□□□□ □□□□□ □□ □□□□ 72 □□□□□ □□ □□□□ □□□□□ □□□□ □□□ 28 □□□□□□ □□ □□□□□□ □□□□ □□□□□□ □□□□□□ □□□□□□□□ □□□□□□□, □□□□□ □□ □□□□□□ □□□□□□□ □□□□□□□□ □□□□□ □□ □□□□□□□□□□□ □□□□□□ □□ □□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□□□□□ □□□□□□□□ □□□□□□
- □□□□□□□ □□□□□□□ □□□□□□□□: □□□□ □□□□ □□ □□□□□□□ □□□□□ □□ □□□□□□ □□ 3 □□□□□□ □□□□□ □□□□□ □□□□□□ □□ □□□□□□□□ □□□□□□□□□ □□ 18-45 □□□□□□ □□ □□□□□ □□ □□□□□□□ □□ □□□□ □□□□ □□□□□ □□□□ □□□□□□□ □□□□□□□□ □□ '□□□□□□ □□□□□' □□□□□□□ □□□□□□□□ □□ '□□□□□□ □□□□□' □□□□□ □□□□□ □□.
- □□□□□□□□□□□ □□ □□ □□□□□□□□: □□□□ □□ □□□□□□ □□□□□□ □□ □□□□□□□□□ □□□□ □□□□ □□ (□□□□□□□□□□□ □□□□□ □□□□□□), □□ □□ □□□□□ "□□□□□□□□□" □□□□□□□□ □□ □□□□□□□ □□, □□ □□□□□□□□□□□ □□ □□ □□□□□□□□ □□ 3 □□□□□□ □□□□ □□□□□□□□ □□□□□□□□□□□ □□ □□ □□□□□ □□□□□ □□□□ □□□□□□□□□-□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□ □□□□ 8 □□ 12 □□□□□□□ □□□□ □□□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□□□ □□ □□□□□ □□□□□□ □□□□□□□□ □□□□□ □□□□ □□□□□□□ □□ □□ □□ □□□□□ □□□□□□□□ □□ □□□□ □□ □□□□□ □□□□ □ □□□□□

6.2 - □□□□ □□ □□□□□□□ □□□□□□□□□ □□□□□

□□ □□□□□□□ □□ □□□□□□: "□□ □□□□□□□ □□□□□□□□□ □□□□□ □□□□□□ □□□□□□ □□□□ □□□□ □□□□ □□, □□ □□□□□□□□ □□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□□ □□ □□□□□□ '□□□□□□□□□□□□' □□ □□ □□ □□□□ □□□□□ □□□□□□" U=U □□□□ □□□□□□ □□ □□□□□ □□ □□□□□□□ □□□□□ □□□□ □□ □□ □□□□□□□□□□ □□□□□ □□ □□□□□ PARTNER □□ PARTNER2 □□□□□□□□□ □□□□□□□ □□□□□□□□ □□□□□ □□□□ □□, □□□□□□□ □□□□□□□ □□ □□□□□□□ "□□□□□□□□□□□□□□□" □□□□□□□ □□ □□□□□□□ □□□□□□ □□□□

- □□□□ □□□□□ □□□□ □□ □□□□ □□□□□□□ □□ □□□□□□ □□□□ □□: □□□□□□ □□□□□ □□□□□□□ □□□□□□□□□ □□ □□□□□□□ □□□□□□□□ □□ □□□□□□□ □□□□□□ □□□□□□□□ □□ □□□□□□□ □□□□ □□ □□□□□□ □□□□□

□□□□ □□□□ □□□□□□□□□□ □□□ □□□□□□□ □□□□□ □□ □□□, □□□□□ □□ □□□□□ □□□□ □□□ □□□□□ □□□□ □□□□ □□□□□□□ □□□ □□□□□□□ □□□□ □□□□ □□□.

- □□□ □□□□ □□ □□ □□□□□ □□□ □□ □□ □□□□□ □□ □□□ □□: □□□□□□□□ □□□□□□ □□□□□□ □□ □□□□ □□□ □□□□□ □□□□ □□□□ □□ □□□□ □□ □□□□□□□□□ □□□□ □□ □□□□□ □□□ □□□ □ □□□□ □□□□□ □□□ □□□ □□□□□ □□□ □□□□□□□□□ □□□□ □□ □□□ □□, □□ □□ □□ □□□□□□□□ □□□□□□□□□□ □□□ □□□□ □□□□□□ □□□□□□□□ □□ □□ □□□□ □□□ □□□□□ □□□□ □□ □□□□□ □□□□□ □□□ □□ □□□□□□□□□□ □□□□ □□□□ □□ □□□ □□□
- □□□□□□□□ □□ □□□□□ □□□□□□□: □□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□ □□ □□□□□□□□□□ □□□ □□ □□□□□ □□□□ □□□ □□□□□ □□ □□□□□□□ □□□□□ - □□□ □□ □□□-□□□ - □□□□□ □□□□□□□ □□ □□□□ □□ □□□□ □□□ □□□ □□□□□□□□ □□□□ □□□□□□ □□□ □□□□□□□ □□□ □□□□ □□□ □□□ □□, □□ □□ □□ □□□ □□□□ □□ □□□ □□ □□□□ □□□□ □□□□□□ □□□□□□□ □□ □□□ □□□□ □□□□ □□ □□□□□□□□ □□□□□ □□□□□ (□□□□□□□, □□□□□ □□ □□ □□ □□□□□) □□ □□□□ □□□ □□□ □□□□ □□□□□ □□ □□□□□ □□□□ □□□□□□□ □□ □□□□□□□□ □□ □□□□□□ □□ □□□□ □□□
- □□□□□□ □□□□□□□□□ □□ □□□□□□: □□□□□□□□ □□ □□□□□ □□ □□□□□□□□□ □□□ □□□□□□ □□ □□□□□ □□ □□□□□□□ □□□□□□□□□□□□□ □□□ □□□□ □□□□ □□ - □□□□, □□□, □□ - □□□□□ □□□ □□□□□□ □□ □□□□□□□□ □□□□ □□□ □□□□□□□□□□□□+ □□□□□□ □□□□□□ □□□□□□□□□ □□□□□□ □□□□ □□□□□□□ □□□□□□ □□□ □□ □□□ □□ □□□□□□ □□ □□□ □□□□ □□□, □□□□□□□□ □□□□□ □□ □□ □□□□□ □□ "□□□□ □□□□□□□□ = □□□□□□□□□□□□□" (U=U) □□ □□□□ □□□□□ □□ □□□□□ □□□□□□□□□ □□ □□ □□□□ □□ □□□□□ □□ □□□□□□□□□ □□□□□□ □□□□□□ □□□ □□□ □□□□□ □□ □□□□□□□□ □□□□□□ □□ □□ □□□□□□□□ □□□

□□□□□□□ 7 — □□□□□□□□□ □□ □□ — □□□□□□ □□ □□□□ □□□□□□□

□ □□□□□□□□□□□ - □□□□□□ □□□□□ □□□□□□ □□ □□□□ □□, □□□□□ □□ □□□□□□□□□□□ □□□□ □□ □□□□ □□□□□.

□□□□□□□□□ □□ □□□□□□ □□□□-□□□□□□□□□ □□ □□□□□□ □□ □□□□□□□□□□□ □□□□ □□ □□□□□□ □□□□□ □□ □□□□□□□□ □□□□□□ □□ □□□□□□□ □□□□ □□□□ □□□□□ □□ - □□ □□ □□□□□□ □□□□ □□ □□□□□□ □□□□□□ □□□□ □□ □□□□ □□ □□□□, □□ □□□□□□ □□□□ □□ GHB □□ □□□□, □□ □□□□□□ □□□□ □□ □□□□□□□□□□□ □□ □□□□ □□□□□, □□□□□□ □□□□□□□□□ □□□□□□□ □□ □□□□□□□□ □□□□□□□ □□ □□□□ □□□□□□□□ □□□□□ □□: □□□□ □□□□□□□□, □□□□□□□□□□□□□□ □□ □□□□, □□□□□□□□□□ □□□□□□□□□, □□□□□□□□ □□□□□ □□ □□□□, □□ □□□□ (□□ □□□□) □□ □□□□□□□□ □□□□ □□ □□□□□ □□□□

□□ □□□□□□ □□□□□ □□ □□ "□□□□□□□□□" □□ □□□□□□ □□ □□ □□□□□□□ □□□□□ □□□□, □□ □□□□-□□□□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□□□ □□ □□□□□ □□□□ □□□□□□□□□ □□ (□□□□ □□□□□□ = "□□□□□□□□□" □□□□□□) □□□□□□□ □□ □□□□□ □□□□ □□ □□□□□□□□ □□ □□ □□□□□□□ □□ □□□□□ □□ (□□□□□□□□ □□□□□□)□ □□□□□ □□□□□□□□ □□ □□ □□□□□□□□□□□ □□□□ □□□□□□□ □□ □□ □□□□□□□□ □□□□ □□□□ □□□□□ □□ ("□□□□□" □□□□□□)□ □□□□□ □□□□□□□□ □□□□□□□□ □□□□□ □□□□ □□□□ □□□□□□ □□□□□□ □□ □□□□□□ □□□□

□□□□□□□□□ □□ □□□□□□ □□□□□□□□ □□□□□□ □□□□□□□□

□□□□□□□□	□□□□□□ □□□□□ □□□□ □□□□ □□□□	□□□□ □□□□
□□□□ □□□□□□□□□ - □□□□ □□ □□□□□□□	□□□□□□□□□ □□ □□□□□□ □□ □□ □□□□ □□□□□□□□□ = "□□□□□□□□□", □□ □□ □□ □□□□ □□□□□□□□□ □□□□□ □□, □□ □□ "□□□□□□□□□" □□ □□□□□□□□□□ □□□□□ □□□□□□□ □□□□□□□ □□ □□□□□ □□□□ □□□□□ □□□□□□ □□ □□□□□□□□ □□□□□□□ □□□□ □□□□ □□ □□□□□ □□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□□□□□ □□□□□□ □□□□ □□.	□□□□ □□□□□□□□□ □□□□□□□□□ □□□□ "□□□□□□□□□" □□□□□□□□□□□□□ □□ □□□□□□□□□□ □□ □□□□□□ □□ □□□□□□□ □□□□□ □□□□ □□□□□□□□ □□ □□□□□□□□ □□□□□ □□□□□□□ □□□□□□□□ □□ □□□□ □□□□□□□□ □□ □□□□□□□□□ "□□□□□□□□□" □□ □□□□□ □□ □□ □□ □□□□□□□ "□□□□□□□□□□□" □□ □□□□□ □□ □□ □□ □□□□□□□ □□□□□□□□ □□□□□□□ □□□□ □□□□□□ □□□□□ □□ □□□□□ □□ - □□ □□ □□□□□ □□□□ □□, □□ □□□□□□□□□□ □□□□□□□□□□ □□ □□□□□ □□□□□
□□□□□ □□ □□□□□□□ □□□□□□□□□□□□□	□□□□□□□□□□, □□□□□□□□□ □□ □□□□□ □□□□□ □□□□□□□□ □□ □□□□□□ □□□□□ □□□□ □□□□□□□□ □□□□ □□□□□□ □□□□□ □□ □□□□□□ □□□□□□□ □□□□ □□□□□□ □□ □□ □□□□□ □□□□□□ □□ - □□□□□ □□□□□□□□□□, □□□□□□□□□□, □□□□□□□□□□, □□ □□□□ □□□□□□ "□□□□□□□□□" □□ □□□□□□□□□□□ □□ □□□□□□□ □□□□□ □□□□□	□□□□□ 90 □□□□□□ □□ □□□□, □□□□□ □□ □□□□□ □□□□ □□ □□□□ □□□□□ □□ □□□□ □□ □□□□□ □□ □□□□□□ □□□□□ □□ - □□ □□□□□□□□□□ □□ □□□□ □□ □□□□□□□□□□□ □□□□□ (□□□□□□□□□□ 05) □□□□□ □□ □□ □□ □□ □□□□□□□□□□ □□□□□□□□□□□ □□□□ □□□□ □□□□□□□ □□□□□ □□ □□□□□□ □□□□□ □□□□□ □□□□□ □□, □□ □□□□□□□□ □□□□ □□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□ □□ "□□□□□□□□□□" □□□□□□□ □□□□□□ □□ □□□□ □□.
□□□□□□□□□□/□□□□□□□ □□□□ (□□□□□ □□ □□□□)□	□□□□□□□□□□ □□ □□□□□□□ □□ □□□□□□□□ □□□□□□ □□ □□ "□□□□□□□□□□" □□□□□ □□ □□□□□□□□ □□□□□ □□ □□□□ □□□□□□□□□□□□ □□, □□ □□ □□□□□□ □□ □□□□□□□□□□ □□□□□□□ □□□□□□ □□	□□ □□□□□□□□□□ □□ □□□□□□□ □□ □□□□□ □□ □□□□□□□ □□ □□□□□□, □□□□□□□ □□ □□□□□-□□□□□□□□ □□□□□ □□□□□□□□□ □□□□□□□□□□□□ □□ □□□□□□ □□□□□□□ □□□□□□□□□ □□□□ □□ □□□□□ □□ □□ □□□□

	[illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□ □□□ □□□□□ □□ □□ □□□, □□ □□□□ □□□□□ □□□ □□□□ □□□□□ □□ □□□□□□ □□□□□□□ □□□ □□□□□ □□□□ □□□□□□□□ □□□

3. 4-7-8 □□□□□ □□□□□ □□ □□□□□□ □□□□ - □□ □□□□□ "□□□□□□□□" □□ □□ □□□ □□ □□□□□□□□□□□□□□□□ □□□ □□ □□□ □□□□□□ □□□□ □□□□ □□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□ □□ □□□□□□ □□□□ □□ □□□, □□ □□□□□□ □□ □□□□□□ □□□□, □□□ □□ □□□□.
4. NAC, L-□□□□□ □□ □□□□□□□□□□ □□□□ □□□□□ □□ □□□□ □□ □□□□□□□□□□□□ □□□□ □□ □□□ □□□□□□□□ □□□ □□ □□□□ □□□□□□□□ □□□ □□□ □□□□□□□ □□□□ □□ □□□□ □□□ □□ □□□ □□□□ □□□□ □□□ □□ □□□□□□□□□ □□□□□□□□□□□ □□□ □□ □□□□□-□□□□□□□ □□□□□□□□ □□□□□ □□ □□□ □□□□□□ □□□□
5. □□□□□□ □□□□ - □□□□□ □□□ □□ □□□□□□ □□□□□□ □□ □□□□□□□ □□ □□□□ □□□ □□□□□□□ □□ □□□□□□ □□□□ □□□□□ □□ □□□□□□□□ □□□ □□ □□□□□ □□ □□□□□ □□ □□□□□□□□□ □□ □□□□□ □□□ □□□□□ □□□□□□□□ □□□ □□□□□□□ (Crystal Meth Anonymous) □□ □□□ □□□□□, □□ □□□ □□□□□□□□□□ □□□□□□□□□□□, □□ □□□ □□□□□□ □□□□□ □□□□□ □□ □□□□ □□ □□ □□ □□□□□□ □□ □□□□□ □□, □□ □□ □□□ □□□□□□□□□ □□ □□□□□□□□ □□□ □□ □□□□□ □□ □□□□□□□ □□□□□□ □□□ □□□□□□□□□□ □□□□ □□□
6. □□□□ □□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□ □□ □□□□□ □□□□□ □□□ □□□ □□ □□□□□□□□ □□□□□□□ □□□□□□ □□□ - □□□ □□□□□□□ □□□ □□□□ □□ □□□□ "□□□□□□□□" (chemsex) □□□□□□ □□ □□□ □□□ □□□□ □□□□□□□, □□□□ □□□□ □□□ □□□□□, □□□□□□□□ □□□□□, □□□□□□□□□□□□ □□□□□□□□□□□ "□□□□□□" □□□□□□□□ □□ □□□□□ □□ □□□□ □□□□ □□ □□□, □□ □□□□□ □□□□□□□□□□□ □□□□□□□□ □□□□ □□; □□□□ □□□ "□□□□□□"-□□□□ □□ □□□□□□□□□□□ □□ □□□□□□□□ □□□□ □□□
7. □□□□ □□□□ □□ □□□ □□□□ □□□□? □□ □□□ □□□□□ □□ □□□□ □□□□ □□ □□□□□ □□ □□□ □□? □□□□ □□□□ □□□□? □□□□□□□□ □□ □□□□□□□ □□□ □□□□ □□□? □□□ □□□□□□ □□ □□□, □□ □□□□ □□□□ □□□□□□□ □□□□□□□□ □□□□□□□□□□□ □□ □□□□□ □□□□□ - □□□□□□, □□□□□□ □□ □□□□□□□ - □□ □□□□□□□□ □□ □□□ □□ □□□□ □□□□□ □□□□□□□□□□ □□ □□□□ □□□ □□□□□

[illegible] 8 - [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [

[illegible] 9 — [illegible]: [illegible]

[illegible]

[illegible]	[illegible]	[illegible]	[illegible], [illegible]
[illegible] ([illegible] 0-7)	[illegible] ([illegible] 3); [illegible]; [illegible]	[illegible]; [illegible]/[illegible]; [illegible]; [illegible]	[illegible] 72 [illegible] (GHB) [illegible]/[illegible] (HIV/STI) [illegible]
[illegible] ([illegible] 1-14)	[illegible] 07, 09, 17, 18; [illegible] ([illegible] 4).	[illegible]-[illegible]; [illegible]; [illegible]; [illegible]; [illegible], [illegible] 1.	NAC [illegible], [illegible] - [illegible], [illegible] 5-HTP, [illegible], [illegible].
[illegible] ([illegible] 1-30)	[illegible] 05, [illegible] 08	[illegible]; [illegible]; [illegible]; [illegible]	[illegible] 24 [illegible] "[illegible]" [illegible] - [illegible]: [illegible] "[illegible]" [illegible]
[illegible] ([illegible] 1-4)	[illegible] 15 ([illegible]), [illegible] 2[illegible]	COMT, GABRA2, MTHFR, DRD2, SLC6A4, CYP2B6.	GABRA2 [illegible], [illegible] GHB [illegible] COMT Val/Val, [illegible] MTHFR [illegible], 5-MTHF [illegible] SLC6A4 short/short, [illegible]-[illegible] [illegible], [illegible]-[illegible] [illegible].
[illegible]	[illegible] 42 ([illegible]); [illegible]	PrEP [illegible] ART [illegible]; [illegible]	[illegible] - [illegible], [illegible]

[illegible] (Ashford).	Ashford Rec. 5 (1), 6; [illegible] [illegible] [illegible].	[illegible] (STI) [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible]; "[illegible]" [illegible] [illegible] [illegible].	[illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible], [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible]

[illegible] - [illegible], [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible].[illegible]., [illegible].[illegible]., [illegible].[illegible]., [illegible].[illegible]., [illegible] [illegible].[illegible]. [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]